257 related articles for article (PubMed ID: 18157011)
1. Increased susceptibility to immune destruction of B16BL6 tumor cells engineered to express a novel pro-Smac fusion protein.
Rüttinger D; Li R; Poehlein CH; Haley D; Walker EB; Hu HM; Fox BA
J Immunother; 2008 Jan; 31(1):43-51. PubMed ID: 18157011
[TBL] [Abstract][Full Text] [Related]
2. Targeting and amplification of immune killing of tumor cells by pro-Smac.
Li R; Rüttinger D; Urba W; Fox BA; Hu HM
Int J Cancer; 2004 Mar; 109(1):85-94. PubMed ID: 14735472
[TBL] [Abstract][Full Text] [Related]
3. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
Winter H; Hu HM; Urba WJ; Fox BA
J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
[TBL] [Abstract][Full Text] [Related]
4. The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack.
Seeger JM; Schmidt P; Brinkmann K; Hombach AA; Coutelle O; Zigrino P; Wagner-Stippich D; Mauch C; Abken H; Krönke M; Kashkar H
Cancer Res; 2010 Mar; 70(5):1825-34. PubMed ID: 20179203
[TBL] [Abstract][Full Text] [Related]
5. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein.
Cho HI; Kim EK; Park SY; Lee SK; Hong YK; Kim TG
Cancer Lett; 2007 Dec; 258(2):189-98. PubMed ID: 17931768
[TBL] [Abstract][Full Text] [Related]
6. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells.
Savai R; Schermuly RT; Pullamsetti SS; Schneider M; Greschus S; Ghofrani HA; Traupe H; Grimminger F; Banat GA
Cancer Res; 2007 Jun; 67(11):5443-53. PubMed ID: 17545626
[TBL] [Abstract][Full Text] [Related]
7. Construction of expression vector of hTERT- hIL18 fusion gene and induction of cytotoxic T lymphocyte response against hTERT.
Tong XM; Zheng SE; Bader A; Yao HP; Wu NP; Altmeyer P; Brockmeyer NH; Jin J
Eur J Med Res; 2008 Jan; 13(1):7-14. PubMed ID: 18226991
[TBL] [Abstract][Full Text] [Related]
8. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
9. Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression.
Liu K; Caldwell SA; Abrams SI
Cancer Res; 2005 May; 65(10):4376-88. PubMed ID: 15899830
[TBL] [Abstract][Full Text] [Related]
10. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.
Kline J; Brown IE; Zha YY; Blank C; Strickler J; Wouters H; Zhang L; Gajewski TF
Clin Cancer Res; 2008 May; 14(10):3156-67. PubMed ID: 18483384
[TBL] [Abstract][Full Text] [Related]
11. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
[TBL] [Abstract][Full Text] [Related]
12. Transfection of Smac sensitizes tumor cells to etoposide-induced apoptosis and eradicates established human hepatoma in vivo.
Zhao J; Jin J; Zhang X; Shi M; Dai J; Wu M; Wang R; Guo Y
Cancer Gene Ther; 2006 Apr; 13(4):420-7. PubMed ID: 16211087
[TBL] [Abstract][Full Text] [Related]
13. La autoantigen translocates to cytoplasm after cleavage during granzyme B-mediated cytotoxicity.
Huang M; Ida H; Arima K; Nakamura H; Aramaki T; Fujikawa K; Tamai M; Kamachi M; Kawakami A; Yamasaki H; Origuchi T; Eguchi K
Life Sci; 2007 Oct; 81(19-20):1461-6. PubMed ID: 17945310
[TBL] [Abstract][Full Text] [Related]
14. Tumor cells expressing a fusion protein of MULT1 and Fas are rejected in vivo by apoptosis and NK cell activation.
Kotturi HS; Li J; Branham-O'Connor M; Stickel SL; Yu X; Wagner TE; Wei Y
Gene Ther; 2008 Oct; 15(19):1302-10. PubMed ID: 18463688
[TBL] [Abstract][Full Text] [Related]
15. Fluorescent antigen-transfected target cell cytotoxic T lymphocyte assay for ex vivo detection of antigen-specific cell-mediated cytotoxicity.
van Baalen CA; Kwa D; Verschuren EJ; Reedijk ML; Boon AC; de Mutsert G; Rimmelzwaan GF; Osterhaus AD; Gruters RA
J Infect Dis; 2005 Oct; 192(7):1183-90. PubMed ID: 16136460
[TBL] [Abstract][Full Text] [Related]
16. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
17. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
[TBL] [Abstract][Full Text] [Related]
18. Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination.
Steitz J; Tormo D; Schweichel D; Tüting T
Cancer Gene Ther; 2006 Mar; 13(3):318-25. PubMed ID: 16151477
[TBL] [Abstract][Full Text] [Related]
19. In vivo antitumor effect of cytotoxic T lymphocytes engineered to produce interferon-gamma by adenovirus-mediated genetic transduction.
Abe J; Wakimoto H; Tsunoda R; Okabe S; Yoshida Y; Aoyagi M; Hirakawa K; Hamada H
Biochem Biophys Res Commun; 1996 Jan; 218(1):164-70. PubMed ID: 8573124
[TBL] [Abstract][Full Text] [Related]
20. Transfer of in vitro expanded T lymphocytes after activation with dendritomas prolonged survival of mice challenged with EL4 tumor cells.
Li J; Theofanous L; Stickel S; Bouton-Verville H; Burgin KE; Jakubchak S; Wagner TE; Wei Y
Int J Oncol; 2007 Jul; 31(1):193-7. PubMed ID: 17549421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
